In summary, our present findings showed that nevirapine could restore iodine uptake in dedifferentiated thyroid cancer by up-regulation of NIS expression and translocation to cell membrane in vitro and in vivo, which provided some valuable evidence that nevirapine might be a promising anticancer drug in treatment of dedifferentiated thyroid cancers. This evidence concerns the gene SLC5A5 and thyroid cancer.